FDA approves two Vuse e-cigarette models

May.13.2022
FDA approves PMTA review for Vuse brand e-cigarettes - Vibe and Ciro, but not for the popular Alto product.

The U.S. Food and Drug Administration (FDA) has approved PMTA applications for two Vuse brand e-cigarettes, Vibe and Ciro. However, Vuse's best-selling product, Alto, is still undergoing PMTA review.

 

Two models of electronic cigarettes, each with two corresponding battery types, as well as accompanying closed tobacco-flavored pods (Vibe with 3% nicotine, Ciro with 1.5% nicotine), have also been approved.

 

However, Vuse Vibe and Vuse Ciro flavors other than tobacco have not passed PMTA review, meaning they cannot be legally sold.

 

The Vuse Vibe and Ciro devices are outdated models with low sales in the market. In contrast, the NJOY Ace approved through PMTA in April is a more popular product in the market.

 

Earlier, two Vuse products received PMTA approval: the Vuse Solo in October 2021 and the Vuse Logic in March 2022.

 

Source: FDA

 

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Italy Formally Submits Detailed Opinion to EU Obstructing Ireland's Disposable Vape Ban
Italy Formally Submits Detailed Opinion to EU Obstructing Ireland's Disposable Vape Ban
Italy's Ministry of Enterprises and Made in Italy has submitted a detailed opinion against Ireland's proposed "Public Health (Single Use Vapes) Bill 2025." Italy argued that the comprehensive ban on disposable vapes lacks scientific evidence, violates the EU principle of the free movement of goods, and conflicts with the existing Tobacco Products Directive.
Apr.10 by 2FIRSTS.ai
Jinjia Shares Discloses 2025 Annual and Q1 2026 Results With Revenue Growth, Profit Pressure and Expanding New Tobacco Business
Jinjia Shares Discloses 2025 Annual and Q1 2026 Results With Revenue Growth, Profit Pressure and Expanding New Tobacco Business
Jinjia Shares’ 2025 annual report summary and first-quarter 2026 report show that the company recorded 2025 revenue of RMB 2.988 billion, up 4.57% year on year, while net profit attributable to shareholders turned to a loss of RMB 346 million. In the first quarter of 2026, revenue rose 58.13% year on year to RMB 1.005 billion, but attributable net profit fell 45.16% to RMB 36.5349 million. The company said both revenue and cost growth were related to the expansion of its new tobacco business.
Apr.28 by 2FIRSTS.ai
Al Fakher Parent AIR Advances U.S. Listing Plan, With Deal Expected in First Half of 2026
Al Fakher Parent AIR Advances U.S. Listing Plan, With Deal Expected in First Half of 2026
AIR Limited and Cantor Equity Partners III, Inc. announced that AIR and AIR Holdings Limited have filed a Form F-4 registration statement with the U.S. Securities and Exchange Commission in connection with their previously announced proposed business combination. Upon closing, the combined company, AIR Global PLC, is expected to be listed on Nasdaq in the United States under the ticker symbol “AIIR.”
Mar.31 by 2FIRSTS.ai
Glas Says FDA Scientific Review Backed Several Flavored Products Before Senior Leaders Blocked Them
Glas Says FDA Scientific Review Backed Several Flavored Products Before Senior Leaders Blocked Them
Glas says newly released internal FDA records show agency scientific reviewers supported authorization for several flavored G2 products before senior leadership halted them. According to documents obtained through a Freedom of Information Act request, FDA’s Office of Science first recommended marketing authorization for all eight products in December 2025 and later supported six of them in February 2026. FDA ultimately authorized only the G2 device and one tobacco-flavored pod in March.
Apr.23 by 2FIRSTS.ai
Nicotine Beyond Tobacco? Cell Study Signals Emerging Shift in Production Systems
Nicotine Beyond Tobacco? Cell Study Signals Emerging Shift in Production Systems
Researchers at the Chinese Academy of Sciences reconstructed nicotine biosynthesis in non-tobacco plants and yeast systems, highlighting how advances in synthetic biology could gradually reshape future nicotine production technologies and challenge regulatory frameworks built around tobacco-derived definitions.
Special Report
May.07
Russian Duma Speaker Says Amendment Giving Regions Power to Ban Vape Sales Is Planned for Adoption in May
Russian Duma Speaker Says Amendment Giving Regions Power to Ban Vape Sales Is Planned for Adoption in May
Russian State Duma Speaker Vyacheslav Volodin said an amendment that would give Russian regions the power to ban vape sales is planned for adoption in May. Volodin said the decision concerns the health of citizens, especially children. He also said doctors have recorded a 30% increase in patients with respiratory diseases caused or aggravated by vape use, with adolescents and people under 35 most often affected.
Apr.24 by 2FIRSTS.ai